CHI's 7th Annual

Clinical Biospecimens Technology and Outsourcing

Tools and Processes to Ensure Quality Oversight

February 9 - 10, 2022 ALL TIMES EST

The availability of high-quality biological specimens, laboratory access, and diagnostics services are of the utmost importance for biomarker-driven clinical trials and future research. The complexity and number of samples collected and analyzed during studies has increased steadily over the years and we need to come up with best practices, operational models, and IT solutions to deal with this volume and complexity. CHI’s 7th Annual Clinical Biospecimens Technology and Outsourcing conference brings together leading experts, clinical trial sponsors, and CROs to discuss challenges and identify actions to improve infrastructure for biomarker-driven clinical trials. Advisory Board: Karina Bienfait, PhD, Executive Director, Specimen Infrastructure & Informed Consent, Global Biospecimen & Imaging Management, Bristol-Myers Squibb Michael Tanen, Director, Clinical Biomarker Specimen Management, Merck & Co. Lynn Wetherwax, R&D Strategy and Operations, Amgen Inc. Brenda Yanak, Vice President, Global Biospecimen & Imaging Management, Bristol-Myers Squibb Co. Mary Zuniga, Consultant, Translational Science Immunology, Eli Lilly & Co.

Wednesday, February 9

ROOM LOCATION: Gatlin E3

BRIDGING LUNCHEON PRESENTATION

12:00 pm Bridging Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
12:30 pm Coffee and Dessert Break in the Exhibit Hall(Gatlin Ballroom BCD)

KEYNOTE LOCATION: Gatlin A1 & A2

DIVERSITY, EQUITY & INCLUSION (DE&I) AND SPEAKING THE LANGUAGE OF BUSINESS AND LEADERSHIP

1:30 pm KEYNOTE PRESENTATION:

Welcome Remarks from CHI and the SCOPE Team

Micah Lieberman, Executive Director, Cambridge Healthtech Institute (CHI)

Thank you all for being here from the SCOPE team: Micah Lieberman, Dr. Marina Filshtinsky, Kaitlin Kelleher, Bridget Kotelly, Mary Ann Brown, Ilana Quigley, Patty Rose, Julie Kostas, and Tricia Michalovicz

1:35 pm KEYNOTE PRESENTATION:

Why Advancing Inclusive Research is a Moral, Scientific, and Business Imperative

Meghan McKenzie, Principal, Inclusion, Patient Insights and Health Equity, Chief Diversity Office, Genentech

Our industry is rightfully focused on the importance of diversity, equity, and inclusion in clinical trials. Many of us have been focused on this in our work and/or in our advocacy, both inside and outside of our organizations for some time. Why is inclusivity so important to PIs and patients? Why is it both a moral and a business imperative? Learn why representation in clinical research matters for your patients and how it shapes good science. The face of the world is changing and your success is tied to reaching ethnic minorities.

2:00 pm KEYNOTE PRESENTATION:

Implicit Bias Around Advocacy and Decision Making: Metrics of DE&I and Speaking the Language of Business and Leadership

Panel Moderator:
Kimberly Richardson, Research Advocate, Founder, Black Cancer Collaborative

What is the perspective of Black professionals and patient advocates as the medical and scientific industries grapple with effective ways to engage minority population?  Where are their voices being heard and what can we learn from the cultural experiences they weave into their research methodologies and daily practices? Panelists will share their perspectives on how the Black voice should be included in advocacy and public and private aspects of clinical research. 

Panelists:
Karriem Watson, PhD, Chief Engagement Officer, NIH
Monique Phillips, Global Diversity and Inclusion Lead, Bristol Myers Squibb Co.
Nikhil Wagle, MD, Assistant Professor, Harvard Medical School, Dana-Farber Cancer Institute
2:45 pm Booth Crawl & Refreshment Break in the Exhibit Hall (Gatlin Ballroom BCD)

ROOM LOCATION: Gatlin E3

IMPLEMENTATION OF NEW BIOMARKER TECHNOLOGIES

Yvonne Beasley, Senior Director, Laboratory Operations, Specimen Processing, Q2 Lab Solutions
3:50 pm

Biomarker Operations Strategies for Managing Outsourced Biospecimen Lifecycles

Lynn Wetherwax, Director, R&D Strategy and Operations, Amgen

The key to a successful outsourcing model is understanding your current and future biospecimen management needs. Biospecimens may be collected for study endpoints or they may be stored until that moment when scientific discovery hinges on biomarker investigation. This presentation will provide an overview of specimen lifecycle strategies that will support a cost-effective outsourced model in a manner that enables flexibility and speed in getting biomarker biospecimens to analytical laboratories.

Yvonne Beasley, Senior Director, Laboratory Operations, Specimen Processing, Q2 Lab Solutions

Sample-level consent management is a critical component of clinical trials, especially follow-on and translational research. Best practice recommendations suggest that sponsors should use a configurable system to define a flexible and manageable set of attributes at the study, country and site levels that can be applied to all samples collected over the duration of the trial. 

4:50 pm PANEL DISCUSSION:

Central Lab Experts Speak: Insights on Best Practices, Operational Models, Processes and Technology

Panel Moderator:
Brenda Yanak, Vice President, Global Biospecimen & Imaging Management, Bristol-Myers Squibb Co.

Effectively partnering with CROs and central labs is a key component to successful clinical biomarker and biospecimens management. Gain insight from SME experts in the vendor community best practices in biospecimens collection and management, and processes and infrastructure to ensure access to high-quality specimens. What lessons can we take from COVID-19 and what innovations are on the horizon to advance precision medicine.  

Panelists:
Lynn Wetherwax, Director, R&D Strategy and Operations, Amgen
Leanne Flye-Blakemore, Lead Scientist, Advanced Cytometric Applications, Labcorp
Kathi Shea, Senior Director, Repository Innovation, Azenta Life Sciences
Tia Parker, Director, ATL Central Lab Operations, Q2 Solutions
Stephanie Weber, Vice President of SampleGISTICS, LabConnect
5:50 pm Close of Day

Thursday, February 10

7:15 am Registration Open and Breakfast (Gatlin Foyer)

ROOM LOCATION: Gatlin E3

BIOMARKER SERVICES IN CLINICAL TRIALS FOR NOVEL THERAPEUTICS

8:20 am

Chairperson's Remarks

Devon Kelly, Associate Director Biorepository, Clinical Operations, CRISPR Therapeutics
8:25 am

Operationalizing Gene Therapy Trials: A Clinical Sample Management Perspective

Devon Kelly, Associate Director Biorepository, Clinical Operations, CRISPR Therapeutics

Effective management of gene therapy trials often requires innovative operational approaches. Biospecimen and associated meta-data journeys can be complex in their initial study start-up and may necessarily deviate from original plans due to rapidly evolving trial designs. Being able to pivot activities based on current operational needs, rather than conventional clinical trial practices, is key to succeeding in these types of trials. Building relationships and aligning expectations with vendors and sites throughout the trial is essential to accomplishing this. Presenters will share experiences and insights from a clinical sample management perspective of operational challenges in the implementation of immune-oncology trials.

8:55 am

Operationalizing Single Cell RNA Sequencing in Clinical Trials

Mary Zuniga, Consultant, Translational Science Immunology, Eli Lilly & Co.

Genomic and genetic testing in clinical trials bring up a set of specific challenges. This presentation will feature some operational and logistical solutions for scRNAseq in clinical trials, starting from sample collection all the way to the data analysis and storage.

9:25 am Sponsored Presentation (Opportunity Available)
9:40 am

Operationalizing ctDNA

Andrew Albright, PhD, Program Manager, Molecular Profiling, Merck & Co., Inc.

For decades, tumor biopsies have been used to diagnose and guide treatment; however, we are entering a new era where circulating tumor DNA (ctDNA) in the blood may provide a substrate for replacing long standing tissue-based assays. But, operational obstacles remain if we are to incorporate ctDNA testing in clinical trials as the field moves from exploratory/RUO testing to using ctDNA as a CDx assay, for enrollment, and stratification.

Stephanie Weber, Vice President, SampleGISTICS, SampleGISTICS, LabConnect

Labconnect continues to lead the industry in clinical trial virtual sample management. The difficulties of sample collection/logistics in advanced therapy studies require a detailed sample management plan. Topics will include key solutions for today’s logistical challenges, leveraging technology and people to reduce risk of sample loss, understanding the criticality of early planning in logistics with an emphasis on involving key experts in sample management for site selection and protocol design.

10:40 am Networking Coffee Break (Gatlin Foyer)

BIOMARKER SERVICES IN CLINICAL TRIALS FOR NOVEL THERAPEUTICS (CONT.)

10:55 am

Chairperson's Remarks

Devon Kelly, Associate Director Biorepository, Clinical Operations, CRISPR Therapeutics
11:00 am

Addressing T Cell Tracking Challenges in Cell Therapy Clinical Trials

Bob O'Hara, Managing Partner, ResultWorks LLC
August Zepka, Senior Director IT Business Systems, Adaptimmune

The personalized nature of cell therapies means that organizations are required by regulators to demonstrate end-to-end visibility across the product supply chain, ensuring chain of custody, identity, and condition. This presentation is based on a program at Adaptimmune, a T cell therapy company, to standup a T cell tracking environment. It illuminates some of the unique challenges and approaches in tracking T cells throughout their lifecycle from patient collection to manufacturing to treatment. It explores some of the challenges in cell therapy T cell tracking that are inherently different from traditional pharmaceutical biospecimen tracking due to the nature of the process.

Jun Luo, Director, Sample Repository, Life Science - Services & Informatics Management, Azenta Life Sciences

What You’ll Learn: Getting the right sample to the right researcher at the right time is paramount in meeting clinical research timelines. Doing so while decreasing overall cost, protecting valuable inventories, and increasing sample utilization is key to comprehensive clinical sample management. Learn how focused sample storage and management can help you achieve these goals and accelerate your clinical research.

12:00 pm Transition to Shared Sessions or Brief Session Break

ROOM CHANGE: Gatlin A2

TOKENIZATION OF CLINICAL TRIAL PARTICIPANTS

12:05 pm PANEL DISCUSSION:

Introducing Unique, Anonymized Identifiers (Tokens) in Clinical Research to Link Participants to Real-World Data

Panel Moderator:
Kyle Holen, Head, Development Design Center, AbbVie, Inc.

This panel discussion will feature use cases and address the key questions regarding clinical trial participant's tokenization such as Why tokens? What are potential pitfalls?  When will this be global?

1:05 pm Transition to Lunch
SCOPE SEND OFF LUNCHEON PRESENTATIONS

Come enjoy a luncheon with your peers while listening to your choice of two compelling industry presentations.

Nekzad Shroff, Vice President, Product Management, Saama Technologies
Aditya Gadiko, Director of Clinical Informatics, Saama Technologies

Today’s medical monitors are under tremendous pressure to quickly identify trends and signals that could impact patient safety and drug efficacy. This critical task is only getting more difficult as the volume of data–and the number of data sources–grows. This session will explore new approaches to medical monitoring, available now, that can simplify workflows and scale to meet the challenges posed by data volume, velocity, and variety.

Nicole Stansbury, Vice President, Clinical Monitoring, Central Monitoring Services, Syneos Health
1:45 pm SCOPE Summit 2022 Adjourns





SCOPE Summit Europe

2024 Conference Programs

Clinical Trial Tech: Venture, Innovation & Partnering
*Separate Registration Required